SCHEMBL21821330

SCHEMBL21821330

CCS(=O)(=O)NC(C)NC(=O)CC(Nc1nc2ccccc2[nH]1)c1cccc(C(F)(F)F)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 1/20 0.43
▸ HTT P42858 1/20 0.43
▸ RAB9A P51151 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ ITGA5 P08648 1/20 0.42
▸ ITGB6 P18564 1/20 0.42
▸ ITGB8 P26012 1/20 0.42
▸ ITGB3 P05106 4/20 0.39
▸ ITGAV P06756 4/20 0.39
▸ MTOR P42345 1/20 0.39
▸ SOS1 Q07889 2/20 0.38
▸ RAF1 P04049 1/20 0.38
▸ BRAF P15056 1/20 0.38
▸ NTRK1 P04629 1/20 0.37
▸ NTRK2 Q16620 1/20 0.37
▸ TEAD4 Q15561 1/20 0.37
▸ MMP1 P03956 1/20 0.37
▸ MMP3 P08254 1/20 0.37
▸ MMP7 P09237 1/20 0.37
▸ MEN1 O00255 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19283608 0.87 ITGA5 (0.45) NPC1HTTRAB9ASMN1; SMN2ITGA5
SCHEMBL21821305 0.85 SMN1; SMN2 (0.48) NPC1HTTRAB9ASMN1; SMN2ITGA5
SCHEMBL21821307 0.85 SMN1; SMN2 (0.48) NPC1HTTRAB9ASMN1; SMN2ITGA5
SCHEMBL21821334 0.85 ITGA5 (0.46) NPC1HTTRAB9ASMN1; SMN2ITGA5
SCHEMBL30645019 0.84 NPC1 (0.47) NPC1HTTRAB9ASMN1; SMN2ITGA5
SCHEMBL20743761 0.84 NPC1 (0.47) NPC1HTTRAB9ASMN1; SMN2ITGA5
SCHEMBL23547183 0.84 NPC1 (0.45) NPC1HTTRAB9ASMN1; SMN2ITGA5
SCHEMBL21821331 0.84 NPC1 (0.45) NPC1HTTRAB9ASMN1; SMN2ITGA5
SCHEMBL19283658 0.83 NPC1 (0.44) NPC1HTTRAB9ASMN1; SMN2ITGA5
SCHEMBL19301055 0.83 ITGA5 (0.47) NPC1HTTRAB9ASMN1; SMN2ITGA5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11274092-B2 Potassium channel inhibitors ACESION PHARMA APS (DK) 2022-03-15 — — US claimed
US-20210188804-A1 NOVEL POTASSIUM CHANNEL INHIBITORS ACESION PHARMA APS (DK) 2021-06-24 — — US claimed
CN-109153667-B Novel potassium channel inhibitors 阿塞西翁制药公司 2021-04-02 — — CN claimed
EP-3419973-B1 NOVEL POTASSIUM CHANNEL INHIBITORS ACESION PHARMA APS (DK) 2020-04-08 — — EP claimed
US-11274092-B2 Potassium channel inhibitors ACESION PHARMA APS (DK) 2022-03-15 — — US disclosed
US-20210188804-A1 NOVEL POTASSIUM CHANNEL INHIBITORS ACESION PHARMA APS (DK) 2021-06-24 — — US disclosed
US-20210188804-A1 NOVEL POTASSIUM CHANNEL INHIBITORS ACESION PHARMA APS (DK) 2021-06-24 — — US disclosed
CN-109153667-B Novel potassium channel inhibitors 阿塞西翁制药公司 2021-04-02 — — CN disclosed
EP-3419973-B1 NOVEL POTASSIUM CHANNEL INHIBITORS ACESION PHARMA APS (DK) 2020-04-08 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210188804-A1 NOVEL POTASSIUM CHANNEL INHIBITORS KCNJ2, KCNN2, KCNN1 NPC1 277/4885HTT 2964/4885RAB9A 1632/4885
US-11274092-B2 Potassium channel inhibitors KCNJ2, KCNJ11, KCNJ1 NPC1 268/4885HTT 2002/4885RAB9A 1920/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback